Physician profile
Joseph Aferzon
NPI 1316960594
$711,615.30
in general payments reported to CMS, 2019-2025
10 companies · $59K in 2025
The $59K reported for 2025 was more than what 99% of Surgery providers received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $146K · 2020: $163K · 2021: $170K · 2022: $53K · 2023: $62K · 2024: $57K · 2025: $59K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Royalty Or License: $116K · Consulting Fee: $50K · Travel and Lodging: $12K · Food and Beverage: $898.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Royalty Or License | $116,477.07 |
| Consulting Fee | $49,940.40 |
| Travel and Lodging | $11,592.54 |
| Food and Beverage | $897.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alphatec Spine, INC | $659,151.50 | 2019-2025 | Amp, Solus Alif, Other - Miscellaneous |
| Spinefrontier, INC. | $51,250.00 | 2020-2023 | Vbr |
| Corelink, LLC | $567.44 | 2019-2020 | |
| Medtronic USA, INC. | $205.25 | 2019 | |
| Abbott Laboratories | $204.68 | 2019-2020 | |
| Boston Scientific Corporation | $89.73 | 2023 | |
| Stryker Corporation | $73.84 | 2019-2021 | |
| Ibsa Pharma INC. | $36.35 | 2021 | |
| Pacira Pharmaceuticals Incorporated | $18.87 | 2019 | |
| Orthofix Medical, INC. | $17.64 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Aferzon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.